Stephen M. Krause, Ph.D.

Dr. Stephen Krause, Ph.D., is a distinguished physiologist and pharmacologist with over 30 years of experience in drug discovery and translational medicine. He has dedicated his career to advancing the understanding of cardiovascular disease, neuroscience, oncology, and metabolic disorders through innovative research and imaging strategies. As President of SK Imaging Consultants, LLC, he leverages his expertise to guide pharmaceutical companies in incorporating imaging techniques such as PET, CT, and SPECT into both discovery and clinical drug development, ensuring precise and effective study design and implementation.

Throughout his career, Dr. Krause has held senior positions at leading organizations, including Eisai, Inc., and Merck, where he specialized in imaging protocol development, pharmacokinetics, target occupancy, and preclinical disease modeling. He also contributed to academic research as an Assistant Professor at Jefferson Medical College. His work spans the full spectrum of early drug development, from target identification to Phase III clinical protocol design, with a focus on integrating translational imaging to drive measurable outcomes.

Dr. Krause is recognized for his leadership, mentoring, and collaborative skills, consistently supporting the professional growth of biologists and interdisciplinary teams. He has authored key regulatory and efficacy documents, including IND submissions, and is highly regarded for his ability to translate complex scientific concepts into actionable strategies. His professional contributions are complemented by his ongoing commitment to advancing translational medicine and improving patient outcomes through innovative imaging applications.

• Johns Hopkins Medical Institutions – Postdoctoral Fellowship, Cardiology
• Virginia Commonwealth University – Ph.D., Physiology
• Michigan State University – B.Sc., Physiology, General

• Ph.D. in Physiology

• Alzheimer's Association International Conference
• Society of Nuclear Medicine and Molecular Imaging (SNMMI)

Brain and Whole Body Imaging Evaluation after Focused Intranasal Delivery of Radiolabeled Compounds to Support CNS Drug Development (Internal Poster)